Print Page  Close Window

SEC Filings

S-1
VITAE PHARMACEUTICALS, INC filed this Form S-1 on 08/12/2014
Entire Document
 

Table of Contents


SUMMARY FINANCIAL DATA

        The following table summarizes our historical financial data as of the dates indicated and for the periods then ended. We have derived the following statement of operations data for the years ended December 31, 2013 and 2012 from our audited financial statements included elsewhere in this prospectus. We have derived the following statement of operations data for the six months ended June 30, 2014 and 2013 and balance sheet data as of June 30, 2014 from our unaudited financial statements included elsewhere in this prospectus. Our unaudited financial statements have been prepared on the same basis as the audited financial statements and, in the opinion of management, include all adjustments, consisting of normal recurring adjustments and accruals, necessary for a fair statement of the information for the interim periods. Our historical results are not necessarily indicative of the results that may be expected in the future, and our interim period results are not necessarily indicative of results to be expected for a full year or any other interim period. The summary of our financial data set forth below should be read together with our financial statements and the related notes to those statements, and the information under "Selected Financial Data" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" included elsewhere in this prospectus.

 
  Year Ended December 31,   Six Months Ended June 30,  
 
  2013   2012   2014   2013  
 
  (in thousands, except share and
per share data)

  (unaudited, in thousands,
except share and per share
data)

 

Statement of operations data:

                         

Collaborative revenues

  $ 22,513   $ 22,348   $ 2,329   $ 1,962  

Operating expenses:

                         

Research and development

    14,917     15,927     9,425     7,584  

General and administrative

    5,406     4,915     2,629     2,680  
                   

Total operating expenses

    20,323     20,842     12,054     10,264  
                   

Operating income (loss)

    2,190     1,506     (9,725 )   (8,302 )

Other (expenses) income:

                         

Other income

    327     243     218     304  

Interest income

    70     101     29     43  

Interest expense

    (1,425 )   (1,627 )   (541 )   (768 )
                   

Total other (expenses) income

    (1,028 )   (1,283 )   (294 )   (421 )

Net income (loss) before income taxes

    1,162     223     (10,019 )   (8,723 )
                   

Net income (loss)

  $ 1,162   $ 223   $ (10,019 ) $ (8,723 )
                   
                   

Per share information:

                         

Net income (loss) per share of common stock, basic and diluted(1)

  $ 0.00   $ 0.00   $ (0.73 ) $ (0.69 )
                   
                   

Basic and diluted weighted average shares outstanding(1)

    12,955,471     12,476,508     13,770,634     12,697,213  
                   
                   

Pro forma net income (loss) per share of common stock:(1)

                         

Basic

  $ 0.01         $ (0.04 )      

Diluted

  $ 0.00         $ (0.04 )      

Pro forma weighted average shares outstanding(1):

                         

Basic

    231,265,212           232,080,375        

Diluted

    240,654,104           232,080,375        

(1)
See Note 2 to our financial statements for an explanation of the method used to calculate net income (loss) per share of common stock, basic and diluted, pro forma net income (loss) per share of common stock, basic and diluted, and the basic and diluted pro forma weighted average shares outstanding used to calculate the pro forma per share amounts.

 

9